RecruitingACTRN12623000424606

Australian Marrow Failure Biobank


Sponsor

Monash University

Enrollment

200 participants

Start Date

Apr 7, 2025

Study Type

Observational

Conditions

Summary

Approximately 5 million people are affected by bone marrow failure syndromes (BMFS) worldwide each year, but individually many of the BMFS are rare. In Australia there are 160 new diagnoses each year, of which 50% do not survive. The rarity of these conditions and the absence of coordinated data and sample collection present barriers to research into biology and optimal treatment of BMFS. In Australia, Maddie Riewoldt's Vision (MRV) has supported a national comprehensive clinical data set on newly diagnosed patients with BMFS through strategic funding of the Aplastic Anaemia Registry and Other Bone Marrow Failure Syndromes Registry (AAR). MRV seeks to build on this initiative by establishing a matched research sample set that will allow new research questions to be asked, provide a feasible and ready-to-go sample set that will support BMFS research. The purpose of the AMFB is to establish a national repository of samples from patients with BMFS to serve as a community resource for clinicians and researchers. Promote nationally consistent, comprehensive diagnostic (including molecular) testing for patients with BMFS. It is hoped that the research from this biobank will provide valuable information to improve the diagnosis, treatment, or care of people with BMFS.


Eligibility

Sex: Both males and females

Plain Language Summary

Simplified for easier understanding

Bone marrow failure syndromes (BMFS) are rare but serious conditions where the bone marrow stops making enough blood cells. These include diseases like aplastic anaemia. Because they are rare, it is hard for researchers to gather enough samples and data to really understand how to best diagnose and treat them. The Australian Marrow Failure Biobank (AMFB) is a national effort to collect blood and tissue samples from patients with these conditions across Australia, creating a shared resource for scientists and doctors. The biobank pairs with an existing national patient registry to build a more complete picture of these diseases and open the door to new research. Anyone with a confirmed or newly suspected diagnosis of a bone marrow failure syndrome is welcome to participate — including children. Blood relatives of people with an inherited form of these conditions may also be invited to contribute samples. There is no age restriction. Participating means donating samples and allowing your data to be shared (anonymously) with researchers working to improve treatments for these conditions.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

The biobank is established to create repository of biological specimens from patients with acquired or inherited bone marrow failure syndromes including germline predisposition to haematological malig

The biobank is established to create repository of biological specimens from patients with acquired or inherited bone marrow failure syndromes including germline predisposition to haematological malignancy. Samples may be linked to patient records in the previously established Aplastic Anaemia and Other Bone Marrow Failure Syndromes Registry (AAR), which houses a comprehensive clinical data set. Patients with bone marrow failure syndrome will be asked to provide the following samples: BASELINE: 1x blood sample, 1x bone marrow aspirate sample and any one of the following germline samples: hair bulb, oral collection, nail clippings, skin fibroblast. ANNUAL: 1x blood sample. FORTUITOUS: 1x bone marrow aspirate sample for each bone marrow biopsy the patient undergoes. Bespoke sample collection of valuable biological samples which are not included above are able to be sent to the biobank with prior ethics approval and discussion with the AMFB team to ensure that appropriate protocols exist to permit storage. Every effort will be made for these research samples to be collected during routine visits and procedures. Patients will continue with annual collections unless they decide to withdraw. Additionally, consented asymptomatic blood relatives of eligible patients who participate in the AMFB will have a singular baseline peripheral blood sample collected.


Locations(5)

Monash Medical Centre - Clayton campus - Clayton

NSW,WA,VIC, Australia

Monash Children’s Hospital - Clayton

NSW,WA,VIC, Australia

Peter MacCallum Cancer Centre - Melbourne

NSW,WA,VIC, Australia

Concord Repatriation Hospital - Concord

NSW,WA,VIC, Australia

Perth Children's Hospital - Nedlands

NSW,WA,VIC, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12623000424606


Related Trials